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Adoptive immunotherapy with T lymphocytes (T cells) modified ex vivo has emerged as a promising therapeutic 
strategy to treat various cancer and autoimmune diseases. T cells engineered to express chimeric antigen 
receptors (CARs) have shown high rates of clinical response in patients with hematological malignancies and 
even early indications of clinical activity in solid tumors. Key steps in the manufacture of CAR T cell therapies 
are the ex vivo transduction of autologous cells with a viral vector and expansion of the genetically modified 
cells. Patient T cells respond inconsistently when cultured in chemically defined media; therefore, basal media 
are typically supplemented with serum. AB serum (ABS) has supply limitations and may not be sufficient to meet 
the expected demand for immunotherapies while fetal bovine serum (FBS) carries a risk of pathogen 
transmission as well as xeno-immunization against bovine antigens. Human platelet lysate (hPL) obtained from 
transfusable donor platelets is widely recognized as a valuable alternative to both FBS and ABS for production 
of clinical cellular therapies. The goal of the present study was to evaluate the feasibility of using a new 
pathogen-reduced human platelet lysate during lentiviral transduction of primary T cells. PR hPL is produced 
with a method that has been demonstrated to reduce pathogens, including enveloped and non-enveloped 
viruses.  Cryopreserved T cells enriched from peripheral blood mononuclear cells of normal donors were 
thawed, activated and cultured in media containing interleukin-2 and different concentrations of FBS, ABS or PR 
hPL. After four days of culture, cells were transduced with a lentiviral vector to deliver a green fluorescent 
protein (GFP) reporter transgene. We found that two days after transduction with CMV-GFP lentivirus the 
percentage of GFP positive cells was generally comparable among the various conditions suggesting that the 
transduction process itself was similarly efficient. Interestingly, cells transduced/cultured in PR hPL consistently 
exhibited brighter GFP compared to cells in ABS with a mean fluorescence intensity (MFI) on average 2.5-fold 
higher (range 1.9 – 3.5-fold, depending on donor).  PGK-GFP and EF1A-GFP lentiviruses were similarly tested 
and expression of the PGK-GFP reporter was also found to be higher with PR hPL. We additionally examined 
the phenotype of cells transduced and cultured in PR hPL using CCR7 and CD62L, markers for less 
differentiated T cells including Tnaive (Tn) and Tcentral memory (Tcm).  Cells in PR hPL exhibited a higher fraction of 
Tn/Tcm T cells than cells in ABS. Emerging in vivo and clinical data in the CAR T field predict that the presence of 
less differentiated T cells is associated with improved persistence following transfer. Our study demonstrates the 
feasibility of using PR hPL for primary T cell modification and expansion. Furthermore, the data predict that one 
may be able to use less lentivirus for a given therapeutic dose of transgene expression, thereby allowing a 
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